Paul Michael Ramirez, Ph.D.
Dr. Paul Michael Ramirez is a specialist in psychometric assessments for CNS research trials. He is currently the President of CNS Ratings, LLC and is Professor of Neuroscience/Neuropsychology, Psychopathology and Psychopharmacology within the Clinical Psychology Doctoral Program at Long Island University in New York City
Dr. Ramirez has made over 200 professional presentations, and over the past 20 years, has provided rater training for assessment scales across CNS indications as well as for the assessment of cognitive disorders throughout North America, South America, Central America, Asia, Eastern and Western Europe, Scandinavia and South Africa. He was also formally co-founder and CEO of the Prophase Training Group (now doing business as ProPhase). Dr. Ramirez has published numerous papers on schizophrenia and other major mental disorders and has been Principal Investigator on grants from the National Institute of Health (NIH), National Cancer Institute (NCI), The National Institute of General Medical Sciences (NIGMS) and pharmaceutical industry sponsors.
Dr. Ramirez is also listed as a contributing author of the Positive and Negative Syndrome Scale (PANSS) and is co-author of the Informant Questionnaire for the PANSS (IQ-PANSS) and co-author of the official MHS Japanese translation of the PANSS.
Dr. Ramirez completed his doctoral degree in Psychology at The City College of The City University of New York with a specialization in Clinical Neuropsychology and a sub specialization in Clinical Psychopathology. He later completed a Postdoctoral Program in Psychopharmacology at Fairleigh Dickerson University. Dr. Ramirez also earned an M.Phil. in Psychology (Conc.: Neuropsychology) from the Graduate School & University Center, City University of New York.
Tom Haskins, Ph.D.
J. Thomas Haskins, Ph.D. is a pharmaceutical professional with over 25 years of research (discovery and clinical Phases I-IV) and management experience (both US and international assignments) in the neurosciences. Tom has experience in the global clinical development of new products in the therapeutic indications of generalized anxiety disorder, panic disorder, major depressive disorder, schizophrenia (injectable antipsychotics), neuropathic pain, hypnotics, stroke and Alzheimer’s disease. Presently Tom is an independent consultant to the pharmaceutical industry, advising clients on clinical development plan content, product differentiation strategies, and protocol design. Earlier he was leader of new product identification and development effort for products originating both internally and externally. Previously, Tom lead matrix style teams for multiple pipeline assets and was responsible for development of these molecules from the bench through the end of Phase 2a (GMP, GLP, GCP, regulatory interactions, biomarker development, etc.). This extensive experience in managing and optimizing research teams, implementing productive research and product differentiation strategies, interfacing with marketing and executive management and highly effective alliance management has resulted in his wide recognition for integrity, diligence, dependability and expertise. Tom is also widely recognized by key opinion leaders and academic institutions for effective and productive sponsor/investigator relationships.
Bill Troetel, Pharm. D.
William M. Troetel, Ph.D., has spent almost forty years in the field of Regulatory Affairs having held positions in the FDA, industry and primarily as a consultant. He has been personally involved in the filing of numerous INDs and NDAs. At present, Dr. Troetel provides regulatory consultations and support to U.S., European and Japanese pharmaceutical and biotech companies on the development and preparation of INDs, NDAs, supplemental NDAs and DMFs, as well as offering advice and strategic planning for drug development programs and participating in interactions with FDA.
Dr. Troetel has done a great deal of teaching and public speaking in the area of Regulatory Affairs, especially on the topic of the format and content of the IND and the NDA, FDA strategic planning and orphan drugs, as well as teaching courses concerning Good Clinical Practices. He served as Course Director for the Center for Professional Advancement teaching the IND/NDA course in the United States and Europe for more than twenty-five years.
Dr. Troetel holds a B. S. degree in Pharmacy from the Columbia University College of Pharmacy, New York, NY; an M.S. degree in Pharmaceutical Chemistry from the Temple University School of Pharmacy in Philadelphia, PA; and a Ph.D. in Pharmacology from the Thomas Jefferson University, Jefferson Medical College, also in Philadelphia.
Liz Masson, Founder and Principal of Clinical Minds, LLC, is a clinical operations executive with 15 years of industry experience, specializing in working with small to medium biotechnology and biopharmaceutical companies. Liz has held progressive management roles in clinical operations and development, with a focus on CRO oversight, site management and relations and rescue work. Liz has a passion for growing highly-engaged teams and ensuring the highest standards of program execution. She earned her B.A. in Leadership and Organization Management from Bay Path University and has taken several post-graduate management, coaching and clinical classes to further develop her skill set. Liz also has extensive experience in neuroscience.